Last reviewed · How we verify
ICP-332 Tablets
ICP-332 is a tyrosine kinase inhibitor that targets specific oncogenic pathways in cancer cells.
ICP-332 is a tyrosine kinase inhibitor that targets specific oncogenic pathways in cancer cells. Used for Hematologic malignancies (phase 3 development).
At a glance
| Generic name | ICP-332 Tablets |
|---|---|
| Sponsor | Beijing InnoCare Pharma Tech Co., Ltd. |
| Drug class | Tyrosine kinase inhibitor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
ICP-332 inhibits tyrosine kinase signaling involved in tumor cell proliferation and survival. The drug is designed to selectively target aberrant kinase activity in cancer, potentially blocking multiple pathways that drive malignant cell growth. It is being developed as an oral small-molecule therapeutic for hematologic and solid malignancies.
Approved indications
- Hematologic malignancies (phase 3 development)
Common side effects
- Gastrointestinal toxicity
- Hematologic abnormalities
- Hepatotoxicity
Key clinical trials
- Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria (PHASE2, PHASE3)
- Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis (PHASE2)
- Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis (PHASE2)
- ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis (PHASE3)
- ICP-332 in Subjects With Non-segmental Vitiligo (PHASE2, PHASE3)
- Phase I Study of ICP-332 in Healthy Subjects (PHASE1)
- Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis (PHASE2)
- A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ICP-332 Tablets CI brief — competitive landscape report
- ICP-332 Tablets updates RSS · CI watch RSS
- Beijing InnoCare Pharma Tech Co., Ltd. portfolio CI